Head to Head Analysis: Oncolytics Biotech (NASDAQ:ONCY) versus AnaptysBio (NASDAQ:ANAB)

Oncolytics Biotech (NASDAQ:ONCY) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Institutional & Insider Ownership

6.8% of Oncolytics Biotech shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 33.7% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Oncolytics Biotech and AnaptysBio’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$20.56 million	($0.30)	-3.32
AnaptysBio	$17.16 million	39.18	-$163.62 million	($6.14)	-4.01

Oncolytics Biotech has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Oncolytics Biotech has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Oncolytics Biotech and AnaptysBio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	0	0	3	0	3.00
AnaptysBio	0	2	7	0	2.78

Oncolytics Biotech currently has a consensus target price of $4.00, suggesting a potential upside of 301.93%. AnaptysBio has a consensus target price of $46.38, suggesting a potential upside of 88.44%. Given Oncolytics Biotech’s stronger consensus rating and higher possible upside, equities analysts clearly believe Oncolytics Biotech is more favorable than AnaptysBio.

Profitability

This table compares Oncolytics Biotech and AnaptysBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-110.66%	-74.28%
AnaptysBio	-711.17%	-161.40%	-35.07%

Summary

Oncolytics Biotech beats AnaptysBio on 9 of the 13 factors compared between the two stocks.

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.